Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|169|5|683-688

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.169, Iss.5, 2015-06, pp. : 683-688

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 1, 2018-01 ,pp. : 24-32

John Wiley & Sons Inc

Access to resources Recommend Favorite

Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: assessment and management of cardiovascular risk factors

By  

INTERNAL MEDICINE JOURNAL, Vol. 48, Iss. S2, 2018-02 ,pp. : 5-13

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treating Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors

By  

Acta Haematologica, Vol. 130, Iss. 3, 2013-06 ,pp. : 192-195

Karger

Access to resources Recommend Favorite

CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib‐resistant chronic myeloid leukaemia

By  

THE JOURNAL OF PATHOLOGY, Vol. 237, Iss. 1, 2015-09 ,pp. : 14-24

John Wiley & Sons Inc

Access to resources Recommend Favorite

A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years

By  

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 40, Iss. 4, 2015-08 ,pp. : 391-397

John Wiley & Sons Inc

Access to resources Recommend Favorite